Using PacBio RS, UCSF Team Shows FLT3-ITD Mutations Are a Valid Therapeutic Target in AML | GenomeWeb

By Molika Ashford

A sequencing study led by the University of California, San Francisco, in collaboration with Pacific Biosciences, has taken advantage of the PacBio RS's long reads to validate the disputed potential of internal tandem duplication mutations in the FLT3 gene as a therapeutic target in acute myeloid leukemia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.